THG1L Antibody

What is THG1L and what are its key cellular functions?

THG1L (tRNA-histidine guanylyltransferase 1 like) is a mitochondrial protein that catalyzes the 3′–5′ addition of guanine to the 5′-end of tRNA-histidine. This enzymatic step is essential for proper recognition of the tRNA and for the fidelity of protein synthesis . Beyond its primary role in tRNA modification, THG1L has several other important cellular functions:

• Functions as a guanyl-nucleotide exchange factor/GEF for the MFN1 and MFN2 mitofusins, thereby regulating mitochondrial fusion

• Contributes to cell survival following oxidative stress by regulating both mitochondrial dynamics and bioenergetic function

• Is transcriptionally upregulated in cells exposed to high glucose levels and in patients with diabetic nephropathy

• Appears to increase mitochondrial biogenesis, which could potentially lead to renal fibrosis in diabetic conditions

THG1L knockout or knockdown results in decreased expression of nuclear respiratory factor-1 (NRF-1), Cytochrome b (cyto B), and ATP synthase subunit 6 (Atp6), as well as decreased Tfam activity, indicating its importance in mitochondrial function .

How is THG1L associated with human disease?

THG1L has been implicated in two main pathological conditions:

1. Autosomal Recessive Spinocerebellar Ataxia (SCAR28):

• Homozygous c.164T>C, p.V55A mutations in THG1L have been identified in multiple Ashkenazi Jewish families

• Clinical presentation includes early onset cerebellar dysfunction, developmental delay, pyramidal signs, and cerebellar atrophy on brain MRI

• The carrier rate for this mutation is approximately 0.8% in the Ashkenazi Jewish population, suggesting a founder mutation

• A different THG1L allele (c.881T>C, p.L294P) has been associated with a more severe phenotype that includes cardiac, gastrointestinal, and hematologic abnormalities in addition to marked developmental delay, epilepsy, and cerebral/cerebellar atrophy

2. Diabetic Nephropathy:

• THG1L (also known as IHG-1 or Induced in High Glucose-1) is upregulated in high glucose conditions and diabetic nephropathy

• Its role in increasing mitochondrial biogenesis may contribute to renal fibrosis

Where is THG1L expressed and localized in cells?

THG1L has a broad expression pattern but shows specific subcellular localization:

Tissue Expression:

• Expressed in many tissues throughout the body

Subcellular Localization:

• Primary localization: Mitochondrion (particularly the outer membrane)

• Secondary localization: Cytoplasm, often found near the nuclear membrane

First identified in yeast, THG1L protein was subsequently found to localize to the mitochondrion in HeLa cells. This dual localization pattern is consistent with its roles in both tRNA processing and mitochondrial dynamics.

What criteria should be used when selecting a THG1L antibody for research applications?

When selecting a THG1L antibody, researchers should consider the following key criteria:

1. Target Specificity:

• Verify antibody specificity through validation methods such as Western blot in tissues/cells known to express THG1L

• Consider antibodies validated on protein arrays containing target protein plus other non-specific proteins

• Check if the antibody detects the expected molecular weight of THG1L (~30-35 kDa)

2. Application Compatibility:

• Ensure the antibody is validated for your specific application (WB, IHC, ICC, ELISA)

• Note dilution recommendations for each application, which can vary significantly:

  • Western Blot: typically 1:500-1:1000

  • Immunohistochemistry: typically 1:20-1:200

  • ELISA: check manufacturer specifications

3. Species Reactivity:

• Confirm reactivity with your experimental species (human, mouse, rat, etc.)

• Cross-reactivity with multiple species can be advantageous for comparative studies

4. Antibody Type:

• Consider whether a polyclonal (broader epitope recognition) or monoclonal (higher specificity) antibody is more suitable for your research question

• For detecting specific isoforms or post-translational modifications, select antibodies raised against specific regions or modified forms

5. Immunogen Information:

• Review the immunogen used to generate the antibody

• Some THG1L antibodies are generated using recombinant proteins corresponding to specific amino acid sequences

How can I validate the specificity of a THG1L antibody for my experimental system?

Rigorous validation is crucial for antibody-based experiments. For THG1L antibodies, consider these validation approaches:

1. Positive and Negative Controls:

• Use cell lines or tissues with known THG1L expression as positive controls

• Include samples where THG1L expression is absent or knockdown/knockout models as negative controls

• The K-562 cell line has been validated as positive for THG1L expression in Western blot

2. RNA Interference:

• Use siRNA or shRNA to knockdown THG1L and confirm reduction in signal

• This approach can demonstrate antibody specificity for the intended target

3. Molecular Weight Verification:

• THG1L has a calculated molecular weight of 34.8 kDa, though it may be observed at approximately 30 kDa in some experimental systems

• Verify that your antibody detects a protein of the expected size

4. Multiple Antibody Approach:

• Use multiple antibodies targeting different epitopes of THG1L

• Consistent results across different antibodies increase confidence in specificity

5. Peptide Competition Assay:

• Pre-incubate the antibody with the immunizing peptide

• This should eliminate or significantly reduce specific binding

6. Mass Spectrometry Confirmation:

• For definitive validation, consider using immunoprecipitation followed by mass spectrometry to confirm target identity

What are the optimal protocols for using THG1L antibodies in Western blot analyses?

For optimal Western blot detection of THG1L, follow these protocol recommendations:

Sample Preparation:

• Extract proteins using standard lysis buffers containing protease inhibitors

• Include phosphatase inhibitors if interested in phosphorylation status

• For mitochondrial proteins like THG1L, consider mitochondrial enrichment protocols

Electrophoresis and Transfer:

• Load 20-50 μg of total protein per lane

• Use 10-12% SDS-PAGE gels for optimal separation

• Transfer to PVDF or nitrocellulose membranes using standard protocols

Blocking and Antibody Incubation:

• Block membranes with 5% non-fat milk or BSA in TBST

• Dilute primary THG1L antibody according to manufacturer recommendations, typically 1:500-1:1000

• Incubate overnight at 4°C for optimal results

• Use appropriate HRP-conjugated secondary antibody at 1:2000-1:5000 dilution

Detection and Analysis:

• Develop using ECL or similar chemiluminescent substrate

• Expected molecular weight is approximately 30-35 kDa

• K-562 cells serve as a reliable positive control

Optimization Tips:

• If high background is observed, increase blocking time or concentration

• For weak signals, consider longer primary antibody incubation or signal amplification systems

• Include positive controls (e.g., K-562 cell lysate) to benchmark signal intensity

How should THG1L antibodies be optimized for immunohistochemistry applications?

Optimizing immunohistochemistry (IHC) protocols for THG1L detection requires attention to several critical factors:

Tissue Preparation:

• Fix tissues in 10% neutral buffered formalin for 24-48 hours

• Process and embed in paraffin following standard protocols

• Section at 4-6 μm thickness

Antigen Retrieval:

• Critical step for detecting THG1L in FFPE tissues

• Use TE buffer pH 9.0 as the primary recommended method

• Alternative: citrate buffer pH 6.0 may be used if TE buffer is unavailable

• Heat-induced epitope retrieval (pressure cooker or microwave) is typically more effective than enzymatic methods

Blocking and Antibody Application:

• Block endogenous peroxidase with 3% H₂O₂

• Block non-specific binding with serum-free protein block

• Dilute THG1L antibodies appropriately, typically 1:20-1:200 for IHC applications

• Incubate at 4°C overnight for optimal sensitivity

Detection and Visualization:

• Use appropriate detection system (e.g., polymer-based or avidin-biotin systems)

• Develop with DAB and counterstain with hematoxylin

• Mount with permanent mounting medium

Validation and Controls:

• Include positive control tissues (human endometrial cancer and colorectal cancer tissues have been validated for some THG1L antibodies)

• Include a negative control (omitting primary antibody)

• Consider dual staining with mitochondrial markers to confirm localization pattern

What approaches can be used to study THG1L function beyond antibody-based methods?

While antibodies are valuable tools, complementary approaches provide more comprehensive insights into THG1L function:

1. Genetic Manipulation:

• CRISPR-Cas9 for THG1L knockout or knock-in studies

• siRNA or shRNA for transient knockdown

• Overexpression systems with tagged constructs (e.g., GFP-THG1L)

2. Functional Assays:

• tRNA guanylyltransferase activity assays to measure enzymatic function

• Mitochondrial fusion/fission assessment using fluorescent markers

• Oxygen consumption rate (OCR) measurements to assess mitochondrial respiration

• ROS detection to evaluate oxidative stress in THG1L-manipulated cells

3. Protein-Protein Interaction Studies:

• Co-immunoprecipitation to identify THG1L binding partners

• Proximity ligation assay to visualize interactions in situ

• Yeast two-hybrid or BioID approaches for interactome mapping

4. Transcriptomic Analysis:

• RNA-Seq to identify genes affected by THG1L manipulation

• qRT-PCR validation of key targets (e.g., NRF-1, cyto B, ATP6)

5. Cell Models for Disease States:

• Patient-derived iPSCs carrying THG1L mutations

• Galactose culture conditions to stress mitochondrial function (as used in patient fibroblast studies)

• High glucose exposure to mimic diabetic conditions and study THG1L upregulation

How can THG1L antibodies be used to investigate mitochondrial dynamics in disease models?

THG1L plays a critical role in mitochondrial fusion and bioenergetics, making it an important target for investigating mitochondrial dynamics in disease:

1. Mitochondrial Morphology Assessment:

• Use co-immunofluorescence with THG1L antibodies and established mitochondrial markers (TOM20, MitoTracker)

• Quantify mitochondrial network parameters (fragmentation, elongation, perinuclear clustering)

• In patient-derived cells with THG1L mutations, abnormal mitochondrial fragmentation and perinuclear accumulation have been observed under galactose culture conditions

2. Disease Model Applications:

• Neurodegenerative Disorders: In cerebellar ataxia models (particularly those with THG1L mutations), investigate mitochondrial morphology in neuronal cells

• Diabetic Nephropathy: Examine THG1L upregulation and consequent mitochondrial biogenesis in renal cells exposed to high glucose

3. Mechanistic Studies:

• Investigate THG1L interaction with MFN1/MFN2 using co-immunoprecipitation followed by Western blot

• Examine the effect of THG1L manipulation on mitochondrial fusion events in real-time using photoactivatable fluorescent proteins

4. Therapeutic Development Applications:

• Use THG1L antibodies to monitor changes in protein expression/localization in response to potential therapeutics targeting mitochondrial dysfunction

• Evaluate whether compounds that modulate mitochondrial dynamics affect THG1L expression or localization

5. Methodological Approach for Disease Models:

• For cerebellar ataxia studies, combine THG1L immunostaining with neuronal markers in patient-derived neurons

• For diabetic nephropathy models, monitor THG1L expression, mitochondrial morphology, and fibrotic markers simultaneously

What is the significance of THG1L in spinocerebellar ataxia research, and how can antibodies contribute to understanding pathogenesis?

THG1L has emerged as an important gene in autosomal recessive spinocerebellar ataxia research (designated as SCAR28), with antibodies providing valuable insights into pathogenesis:

1. Genetic and Clinical Context:

• Homozygous c.164T>C (p.V55A) THG1L mutations cause autosomal recessive cerebellar ataxia in Ashkenazi Jewish families

• Clinical phenotype includes cerebellar dysfunction, developmental delay, dysarthria, pyramidal signs, and cerebellar atrophy

• Carrier frequency of approximately 0.8% in Ashkenazi Jewish populations suggests a founder mutation

2. Research Applications of THG1L Antibodies:

• Protein Stability Assessment: Western blot analysis can determine if the V55A mutation affects protein stability or levels

• Localization Studies: Immunocytochemistry can reveal whether mutant THG1L shows altered subcellular localization

• Patient Sample Analysis: IHC on patient-derived tissues can evaluate THG1L expression patterns in affected tissues

3. Mechanistic Studies:

• Mitochondrial Pathology: THG1L mutations lead to abnormal mitochondrial fragmentation and perinuclear clustering under metabolic stress conditions

• tRNA Processing: Antibodies can help investigate whether mutant THG1L affects tRNA-His guanylyltransferase activity

• Oxidative Stress: Combining THG1L immunodetection with oxidative stress markers can reveal connections between THG1L dysfunction and cellular damage

4. Experimental Approach in SCAR28 Research:

• Generate patient-specific iPSCs harboring THG1L mutations

• Differentiate into neurons and glia for disease modeling

• Use THG1L antibodies in combination with mitochondrial and neuronal markers

• Evaluate responses to metabolic stress (e.g., galactose medium) to reveal pathogenic mechanisms

5. Potential Therapeutic Implications:

• Monitor THG1L expression/function in response to compounds targeting mitochondrial function

• Use THG1L antibodies as tools to screen for therapeutic candidates that restore proper mitochondrial dynamics

How reliable are current THG1L antibodies for detecting specific mutations associated with disease?

The reliability of THG1L antibodies for detecting disease-associated mutations requires careful consideration:

1. Detection Limitations:

• Current commercial antibodies are generally not designed to specifically detect mutant THG1L proteins (such as V55A)

• Standard antibodies will detect both wild-type and mutant proteins unless specifically designed against the mutation site

2. Research Strategies for Mutation Studies:

3. Alternative Approaches for Mutation Detection:

• Use genetic methods (sequencing, PCR-RFLP) for definitive mutation identification

• For functional studies, combine antibody detection with other methods:

  • Mass spectrometry for protein identification and quantification

  • Cellular phenotyping (mitochondrial morphology analysis)

  • Biochemical assays for tRNA guanylyltransferase activity

4. Experimental Design Considerations:

• Include appropriate controls (wild-type, heterozygous, and homozygous samples)

• Validate findings with multiple methodologies

• Consider using tagged constructs (wild-type vs. mutant) for overexpression studies when discrimination is essential

What are the common challenges when using THG1L antibodies, and how can they be addressed?

Researchers working with THG1L antibodies may encounter several challenges that can be systematically addressed:

1. Non-specific Banding in Western Blots:

• Challenge: Multiple bands appearing near or away from the expected 30-35 kDa size

• Solutions:

  • Optimize antibody dilution (typically 1:500-1:1000)

  • Increase blocking time or concentration (5% BSA may reduce background compared to milk)

  • Include detergents like Tween-20 in wash buffers

  • Consider using gradient gels for better separation

  • Validate with positive controls (e.g., K-562 cells)

2. Weak Signal in Immunohistochemistry:

• Challenge: Poor or absent staining despite expected THG1L expression

• Solutions:

  • Optimize antigen retrieval (TE buffer pH 9.0 is recommended, with citrate buffer pH 6.0 as an alternative)

  • Use signal amplification systems (tyramide signal amplification)

  • Increase primary antibody concentration or incubation time

  • Ensure tissue fixation was appropriate (overfixation can mask epitopes)

  • Test multiple antibodies targeting different epitopes

3. Background in Immunocytochemistry:

• Challenge: High non-specific staining obscuring specific signal

• Solutions:

  • Increase blocking time and concentration

  • Include serum from the secondary antibody species in blocking solution

  • Reduce primary and secondary antibody concentrations

  • Include 0.1-0.3% Triton X-100 for better penetration in fixed cells

  • Consider low-autofluorescence mounting media

4. Cross-reactivity Issues:

• Challenge: Antibody detects proteins other than THG1L

• Solutions:

  • Check antibody validation data for potential cross-reactivity

  • Use knockout or knockdown controls

  • Consider antibodies validated on protein arrays containing THG1L plus other proteins

  • Perform peptide competition assays to verify specificity

5. Storage and Stability Issues:

• Challenge: Decreased antibody performance over time

• Solutions:

  • Store according to manufacturer recommendations (typically -20°C with glycerol)

  • Avoid repeated freeze-thaw cycles

  • Consider making small aliquots upon receipt

  • Note manufacturer expiration dates

How can inconsistencies in THG1L antibody results between different detection methods be reconciled?

Discrepancies between different detection methods using THG1L antibodies may arise due to various factors:

1. Method-Specific Epitope Accessibility:

• Issue: An epitope may be accessible in denatured conditions (Western blot) but masked in native conditions (IHC/ICC)

• Reconciliation Approach:

  • Use antibodies targeting different epitopes for different applications

  • For Western blots, ensure complete protein denaturation

  • For IHC/ICC, optimize antigen retrieval methods (TE buffer pH 9.0 recommended)

2. Expression Level Detection Thresholds:

• Issue: Different methods have varying sensitivity limits

• Reconciliation Approach:

  • For low-expression samples, use more sensitive techniques (e.g., immunoprecipitation followed by Western blot)

  • Adjust exposure times in Western blot to detect low-abundance signals

  • Use signal amplification in IHC/ICC (tyramide signal amplification)

3. Post-translational Modifications:

• Issue: Modifications may affect antibody binding differently across methods

• Reconciliation Approach:

  • Consider antibodies that are insensitive to post-translational modifications

  • Use phosphatase or deglycosylation treatments when appropriate

  • Include controls for post-translational modification states

4. Subcellular Localization Effects:

• Issue: THG1L's dual localization (mitochondria and cytoplasm) may appear differently across methods

• Reconciliation Approach:

  • Use subcellular fractionation for Western blot analysis

  • Perform co-localization studies with mitochondrial markers in IHC/ICC

  • Consider context-specific expression patterns (e.g., stress conditions may alter localization)

5. Methodological Validation:

• Issue: Each technique may require different validation approaches

• Reconciliation Approach:

  • Validate each technique independently with appropriate controls

  • Use orthogonal methods to confirm key findings

  • Consider method-specific optimization for each antibody

What standards should be followed when reporting THG1L antibody-based research findings?

To ensure reproducibility and reliability in THG1L antibody-based research, adhere to these reporting standards:

1. Comprehensive Antibody Information:

• Manufacturer and catalog number

• Clone designation for monoclonal antibodies

• Host species and antibody type (polyclonal/monoclonal)

• Immunogen details when available

• Lot number (particularly important for polyclonal antibodies)

2. Detailed Methodology:

• Complete sample preparation protocols

• Buffer compositions and pH values

• Antigen retrieval methods (TE buffer pH 9.0 or citrate buffer pH 6.0 for IHC)

• Blocking conditions and duration

• Primary and secondary antibody dilutions and incubation times/temperatures

• Detection systems and parameters

3. Validation Evidence:

• Positive and negative controls used

• Supporting evidence for antibody specificity

• Images of full-length blots with molecular weight markers

• Representative images with scale bars

4. Quantification Methods:

• Software and algorithms used for quantification

• Normalization approach for Western blots

• Scoring system for IHC (if applicable)

• Statistical methods for data analysis

5. Repository Information:

• Consider depositing detailed protocols in repositories like protocols.io

• For large datasets, provide access to raw images in repositories like Zenodo

• Include Research Resource Identifiers (RRIDs) for antibodies

Example Reporting Format for Methods Section:
"THG1L protein expression was analyzed by Western blot using rabbit polyclonal anti-THG1L antibody (Vendor, Cat#ABC123, RRID:AB_123456, Lot#789, 1:500 dilution) raised against recombinant protein corresponding to amino acids X-Y of human THG1L. Membranes were blocked with 5% non-fat milk in TBST for 1 hour at room temperature, incubated with primary antibody overnight at 4°C, and detected using HRP-conjugated goat anti-rabbit IgG (Vendor, Cat#DEF456, 1:5000). K-562 cell lysate served as a positive control. Specificity was previously validated by siRNA knockdown."

What are the key applications and species reactivity profiles of commonly used THG1L antibodies?

Table compiled from available search results . Researchers should verify current specifications with manufacturers as products may be updated.

What is the molecular and subcellular context of THG1L that researchers should consider?

Table compiled from available search results. This information provides important context for experimental design and data interpretation in THG1L research.